Foundayo (orforglipron) is Eli Lilly's once-daily oral, non-peptide GLP-1 receptor agonist, FDA-approved April 1, 2026 for chronic weight management and sold through LillyDirect. It is a different molecule from semaglutide and not a generic of Ozempic, Wegovy or Rybelsus.
At a glance
- Generic name: orforglipron
- Manufacturer: Eli Lilly
- Self-pay via LillyDirect (archived pages dated September 25, 2026): $149 (0.8 mg); $149 (2.5 mg) and $199 (5.5 mg), reduced through December 31, 2026; $299 (9 mg); $299 (14.5 and 17.2 mg with refills within 45 days; regular $349)
- Medicare: Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): a $50 copay for eligible Part D enrollees for Foundayo, Wegovy or the Zepbound KwikPen; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible and use their Part D plan instead.
FDA-approved indications
- Chronic weight management in adults with obesity, or overweight with at least one weight-related condition (approved April 1, 2026)
- No U.S. type 2 diabetes indication as of October 16, 2026
ACHIEVE-4 (Lancet, September 2026): in 2,749 adults with type 2 diabetes at increased CV risk, orforglipron was non-inferior to insulin glargine for major CV events (4.2% vs 5.0%; HR 0.84, 95% CI 0.59 to 1.20).
Standard dosing
- Once-daily oral tablet, non-peptide
- Strengths: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg; the prescriber steps the dose up following the label
- Women using birth-control pills: the label advises a non-oral or backup method for 30 days after starting and after each dose increase